AbbVie’s Apogee deal comes with an $8B IOU

More pipeline, more debt

AbbVie has made a habit of buying its way into tomorrow’s drug pipeline, and this time the bill is chunky. The company is piling on roughly $8 billion in debt tied to its Apogee deal, which is basically the corporate version of swiping the card because the thing in the cart looks too good to leave behind.

Why dividend investors are side-eyeing it

If you own ABBV for the dividend, this is the part where you lean in. More debt can be totally fine when the acquired asset looks promising, but it still means higher interest costs and a bit less room for error if the pipeline doesn’t sing.

The market math

For a big pharma giant, this isn’t a survival moment — it’s a balance-sheet choice. The question is whether the Apogee deal turns into a growth engine or just another expensive reminder that drug development is basically a very fancy slot machine.

Big picture: AbbVie is betting that future medicines will cover today’s borrowing. That can work out beautifully… right up until it doesn’t.